Compare USLM & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USLM | AAPG |
|---|---|---|
| Founded | 1948 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 2.9B |
| IPO Year | N/A | 2025 |
| Metric | USLM | AAPG |
|---|---|---|
| Price | $121.95 | $30.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $48.50 |
| AVG Volume (30 Days) | ★ 57.0K | 5.1K |
| Earning Date | 10-29-2025 | 11-19-2025 |
| Dividend Yield | ★ 0.20% | N/A |
| EPS Growth | ★ 32.23 | N/A |
| EPS | ★ 4.55 | N/A |
| Revenue | ★ $364,849,000.00 | $54,524,554.00 |
| Revenue This Year | $22.64 | N/A |
| Revenue Next Year | $8.38 | $368.64 |
| P/E Ratio | $26.69 | ★ N/A |
| Revenue Growth | ★ 20.27 | N/A |
| 52 Week Low | $80.47 | $16.50 |
| 52 Week High | $154.79 | $48.45 |
| Indicator | USLM | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 52.60 | 50.39 |
| Support Level | $116.76 | $30.00 |
| Resistance Level | $122.10 | $33.09 |
| Average True Range (ATR) | 3.33 | 0.83 |
| MACD | 0.50 | 0.14 |
| Stochastic Oscillator | 65.33 | 72.07 |
United States Lime & Minerals Inc is engaged in the business of manufacturing lime and limestone products including PLS, quicklime, hydrated lime and lime slurry. It supplies its products predominantly to the construction (including highway, road, and building contractors), industrial (including paper and glass manufacturers), environmental (including municipal sanitation and water treatment facilities and flue gas treatment processes), metals (including steel producers), oil and gas services, roof shingle manufacturers and agriculture (including poultry and cattle feed producers) industries. The company operates through its Lime and Limestone Operations segment.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.